Replies to post #142415 on Biotech Values

[DewDiligence]

…traditional chemo does not show this subgroup pfs harm to anywhere near the degree it often pops up in the more targetted kinase actors. But again, I'd need to do more research to make it less anecdotal.

I think you’re on the right track. Moreover, I don’t find it counter-intuitive that a targeted drug could accelerate tumor growth (thereby shortening PFS) in certain patients who are especially susceptible to alternative growth pathways triggered by the targeted drug being administered.

[biomaven0]

harm done to pfs in Met- patients in MetMab plus Tarceva

That space is particularly confusing, with the possibility of agonism instead of antagonism and the inverse results seen by Aveo's rival compound.

I sometimes think we would learn a lot more with an intensive study of a few patients than we do with a traditional trial.

Peter